New drug duo aims to outsmart tough cancers
NCT ID NCT01012817
Summary
This study tested a two-drug combination (veliparib and topotecan) for people with advanced solid tumors or ovarian cancer that has come back after initial treatment. The first phase aimed to find the safest and most effective dose. The second phase focused on seeing if the combination could shrink tumors and delay cancer growth in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Parkland Memorial Hospital
Dallas, Texas, 75235, United States
-
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, 60451, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Chicago Medicine-Orland Park
Orland Park, Illinois, 60462, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.